Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.46 USD | -1.10% |
|
-3.77% | -17.30% |
Jun. 03 | Tranche Update on Copart, Inc.'s Equity Buyback Plan announced on February 20, 2003. | CI |
May. 23 | JPMorgan Adjusts Price Target on Copart to $55 From $60, Maintains Neutral Rating | MT |
Summary: Copart, Inc.
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Highlights: Copart, Inc.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses: Copart, Inc.
- The firm trades with high earnings multiples: 30.64 times its 2025 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings Chart: Copart, Inc.
Source: Surperformance
ESG chart: Copart, Inc.
Source: MSCI
Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
---|---|---|---|---|---|
45.89B | |||||
242B | |||||
149B | |||||
145B | |||||
121B | |||||
93.33B | |||||
35.54B | |||||
7.83B | |||||
5.6B | |||||
5.17B | |||||
Average | 85.1B | ||||
Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
A
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
-
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CPRT Stock
- Ratings Copart, Inc.
Select your edition
All financial news and data tailored to specific country editions